Neurocrine Biosciences, Inc. (0K6R.L)
USD 100.59
(1.7%)
USD 100.59
(1.7%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.88 Billion USD | 26.76% |
| 2022 | 1.48 Billion USD | 31.34% |
| 2021 | 1.13 Billion USD | 8.38% |
| 2020 | 1.04 Billion USD | 32.71% |
| 2019 | 788.1 Million USD | 74.65% |
| 2018 | 451.24 Million USD | 179.19% |
| 2017 | 161.62 Million USD | 977.51% |
| 2016 | 15 Million USD | -24.12% |
| 2015 | 19.76 Million USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 2.91 Million USD | -94.51% |
| 2012 | 53.14 Million USD | -31.36% |
| 2011 | 77.41 Million USD | 131.08% |
| 2010 | 33.5 Million USD | 1034.47% |
| 2009 | 2.95 Million USD | -25.71% |
| 2008 | 3.97 Million USD | 224.75% |
| 2007 | 1.22 Million USD | -96.88% |
| 2006 | 39.23 Million USD | -68.33% |
| 2005 | 123.88 Million USD | 45.45% |
| 2004 | 85.17 Million USD | -38.76% |
| 2003 | 139.07 Million USD | 670.73% |
| 2002 | 18.04 Million USD | -56.25% |
| 2001 | 41.24 Million USD | 182.71% |
| 2000 | 14.58 Million USD | -13.17% |
| 1999 | 16.8 Million USD | 5.0% |
| 1998 | 16 Million USD | -38.7% |
| 1997 | 26.1 Million USD | 35.94% |
| 1996 | 19.2 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 622.1 Million USD | 5.4% |
| 2024 Q1 | 515.29 Million USD | 0.02% |
| 2024 Q2 | 590.2 Million USD | 14.54% |
| 2023 Q2 | 452.7 Million USD | 7.68% |
| 2023 FY | 1.88 Billion USD | 26.76% |
| 2023 Q1 | 420.4 Million USD | 2.04% |
| 2023 Q4 | 515.2 Million USD | 3.29% |
| 2023 Q3 | 498.8 Million USD | 10.18% |
| 2022 Q1 | 310.6 Million USD | -0.45% |
| 2022 Q4 | 412 Million USD | 6.21% |
| 2022 Q3 | 387.9 Million USD | 2.56% |
| 2022 Q2 | 378.2 Million USD | 21.76% |
| 2022 FY | 1.48 Billion USD | 31.34% |
| 2021 Q3 | 296 Million USD | 2.46% |
| 2021 Q4 | 312 Million USD | 5.41% |
| 2021 Q2 | 288.9 Million USD | 22.1% |
| 2021 FY | 1.13 Billion USD | 8.38% |
| 2021 Q1 | 236.6 Million USD | -4.56% |
| 2020 Q2 | 302.4 Million USD | 27.54% |
| 2020 FY | 1.04 Billion USD | 32.71% |
| 2020 Q3 | 258.5 Million USD | -14.52% |
| 2020 Q4 | 247.9 Million USD | -4.1% |
| 2020 Q1 | 237.1 Million USD | -2.87% |
| 2019 FY | 788.1 Million USD | 74.65% |
| 2019 Q2 | 183.58 Million USD | 32.64% |
| 2019 Q3 | 222.09 Million USD | 20.98% |
| 2019 Q4 | 244.1 Million USD | 9.91% |
| 2019 Q1 | 138.4 Million USD | 5.26% |
| 2018 Q4 | 131.49 Million USD | -13.35% |
| 2018 Q2 | 96.9 Million USD | 36.32% |
| 2018 Q1 | 71.08 Million USD | -24.79% |
| 2018 FY | 451.24 Million USD | 179.19% |
| 2018 Q3 | 151.75 Million USD | 56.6% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q3 | 60.77 Million USD | 859.34% |
| 2017 FY | 161.62 Million USD | 977.51% |
| 2017 Q4 | 94.51 Million USD | 55.52% |
| 2017 Q2 | 6.33 Million USD | 0.0% |
| 2016 FY | 15 Million USD | -24.12% |
| 2016 Q2 | - USD | -100.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | 15 Million USD | 0.0% |
| 2015 Q2 | - USD | -100.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q1 | 19.76 Million USD | 0.0% |
| 2015 FY | 19.76 Million USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | -100.0% |
| 2014 Q1 | - USD | -100.0% |
| 2013 Q1 | 730 Thousand USD | -96.67% |
| 2013 FY | 2.91 Million USD | -94.51% |
| 2013 Q4 | 730 Thousand USD | 0.14% |
| 2013 Q3 | 729 Thousand USD | -0.14% |
| 2013 Q2 | 730 Thousand USD | 0.0% |
| 2012 Q3 | 9.35 Million USD | -11.47% |
| 2012 Q4 | 21.94 Million USD | 134.55% |
| 2012 FY | 53.14 Million USD | -31.36% |
| 2012 Q1 | 11.26 Million USD | 1.41% |
| 2012 Q2 | 10.56 Million USD | -6.2% |
| 2011 Q2 | 12.15 Million USD | -2.84% |
| 2011 Q4 | 11.11 Million USD | -73.32% |
| 2011 FY | 77.41 Million USD | 131.08% |
| 2011 Q3 | 41.63 Million USD | 242.47% |
| 2011 Q1 | 12.51 Million USD | -8.38% |
| 2010 Q3 | 14.44 Million USD | 211.18% |
| 2010 Q2 | 4.64 Million USD | 516.6% |
| 2010 Q1 | 753 Thousand USD | 1.76% |
| 2010 FY | 33.5 Million USD | 1034.47% |
| 2010 Q4 | 13.65 Million USD | -5.47% |
| 2009 Q4 | 740 Thousand USD | 0.95% |
| 2009 Q3 | 733 Thousand USD | 0.0% |
| 2009 FY | 2.95 Million USD | -25.71% |
| 2009 Q1 | 747 Thousand USD | 2.47% |
| 2009 Q2 | 733 Thousand USD | -1.87% |
| 2008 Q1 | 1.75 Million USD | 229.14% |
| 2008 Q2 | 734 Thousand USD | -58.08% |
| 2008 Q3 | 761 Thousand USD | 3.68% |
| 2008 FY | 3.97 Million USD | 224.75% |
| 2008 Q4 | 729 Thousand USD | -4.2% |
| 2007 FY | 1.22 Million USD | -96.88% |
| 2007 Q4 | 532 Thousand USD | -1.48% |
| 2007 Q3 | 540 Thousand USD | 1025.0% |
| 2007 Q2 | 48 Thousand USD | -53.85% |
| 2007 Q1 | 104 Thousand USD | -98.9% |
| 2006 Q4 | 9.44 Million USD | 778.96% |
| 2006 Q1 | 19.47 Million USD | 38.02% |
| 2006 FY | 39.23 Million USD | -68.33% |
| 2006 Q3 | 1.07 Million USD | -88.38% |
| 2006 Q2 | 9.24 Million USD | -52.54% |
| 2005 Q1 | 11.86 Million USD | -35.82% |
| 2005 FY | 123.88 Million USD | 45.45% |
| 2005 Q2 | 33.16 Million USD | 179.58% |
| 2005 Q3 | 64.74 Million USD | 95.2% |
| 2005 Q4 | 14.11 Million USD | -78.21% |
| 2004 Q4 | 18.48 Million USD | -46.73% |
| 2004 Q3 | 34.7 Million USD | 130.59% |
| 2004 Q2 | 15.04 Million USD | -11.17% |
| 2004 Q1 | 16.94 Million USD | -37.57% |
| 2004 FY | 85.17 Million USD | -38.76% |
| 2003 FY | 139.07 Million USD | 670.73% |
| 2003 Q4 | 27.13 Million USD | -7.26% |
| 2003 Q3 | 29.25 Million USD | -34.93% |
| 2003 Q2 | 44.96 Million USD | 19.23% |
| 2003 Q1 | 37.71 Million USD | 872.56% |
| 2002 FY | 18.04 Million USD | -56.25% |
| 2002 Q4 | 3.87 Million USD | -22.18% |
| 2002 Q1 | 4.95 Million USD | -61.37% |
| 2002 Q2 | 4.22 Million USD | -14.73% |
| 2002 Q3 | 4.98 Million USD | 17.89% |
| 2001 Q4 | 12.83 Million USD | -40.57% |
| 2001 Q3 | 21.59 Million USD | 548.83% |
| 2001 Q2 | 3.32 Million USD | -4.59% |
| 2001 Q1 | 3.48 Million USD | -1.61% |
| 2001 FY | 41.24 Million USD | 182.71% |
| 2000 FY | 14.58 Million USD | -13.17% |
| 2000 Q1 | 2.77 Million USD | -33.86% |
| 2000 Q3 | 5.32 Million USD | 80.93% |
| 2000 Q4 | 3.54 Million USD | -33.4% |
| 2000 Q2 | 2.94 Million USD | 5.9% |
| 1999 FY | 16.8 Million USD | 5.0% |
| 1999 Q4 | 4.2 Million USD | -19.23% |
| 1999 Q2 | 3.8 Million USD | 5.56% |
| 1999 Q1 | 3.6 Million USD | -20.0% |
| 1999 Q3 | 5.2 Million USD | 36.84% |
| 1998 Q2 | 2.3 Million USD | -43.9% |
| 1998 Q3 | 5.1 Million USD | 121.74% |
| 1998 Q4 | 4.5 Million USD | -11.76% |
| 1998 FY | 16 Million USD | -38.7% |
| 1998 Q1 | 4.1 Million USD | -33.87% |
| 1997 Q4 | 6.2 Million USD | 0.0% |
| 1997 Q1 | 8.9 Million USD | -4.3% |
| 1997 FY | 26.1 Million USD | 35.94% |
| 1997 Q3 | 6.2 Million USD | 29.17% |
| 1997 Q2 | 4.8 Million USD | -46.07% |
| 1996 Q2 | 5.5 Million USD | 150.0% |
| 1996 FY | 19.2 Million USD | 0.0% |
| 1996 Q1 | 2.2 Million USD | 0.0% |
| 1996 Q3 | 2.2 Million USD | -60.0% |
| 1996 Q4 | 9.3 Million USD | 322.73% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| uniQure N.V. | 15.84 Million USD | -11811.254% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -53817.143% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -5938.913% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 72.383% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -6935.38% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | -3.217% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -372.536% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -21912.131% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -597.376% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 21.996% |
| bluebird bio, Inc. | 29.49 Million USD | -6297.6% |
| Blueprint Medicines Corporation | 249.38 Million USD | -656.717% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -8899.905% |
| Imunon, Inc. | - USD | -Infinity% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -291.21% |
| Dynavax Technologies Corporation | 232.28 Million USD | -712.411% |
| Editas Medicine, Inc. | 78.12 Million USD | -2315.55% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -79.844% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -1522.14% |
| Exelixis, Inc. | 1.83 Billion USD | -3.108% |
| FibroGen, Inc. | 147.75 Million USD | -1177.208% |
| Geron Corporation | 237 Thousand USD | -796144.726% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | -127.566% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -1385.391% |
| Illumina, Inc. | 4.5 Billion USD | 58.102% |
| Incyte Corporation | 3.69 Billion USD | 48.937% |
| Insmed Incorporated | 305.2 Million USD | -518.3% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -5102.205% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | -139.587% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -158613.204% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 87.406% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 50.186% |
| Evolus, Inc. | 202.08 Million USD | -833.815% |
| Myriad Genetics, Inc. | 678.4 Million USD | -178.169% |
| OPKO Health, Inc. | 863.49 Million USD | -118.542% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | -51.777% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -210.623% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 98.722% |
| Waters Corporation | 2.95 Billion USD | 36.169% |
| Zoetis Inc. | 8.54 Billion USD | 77.913% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 80.879% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 95.597% |
| Biogen Inc. | 9.83 Billion USD | 80.814% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -970.804% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 85.614% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 28473.177% |
| Nektar Therapeutics | 90.12 Million USD | -1993.939% |
| TG Therapeutics, Inc. | 233.66 Million USD | -707.62% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Perrigo Company plc | 4.65 Billion USD | 59.466% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |